COSCIENS Biopharma Inc. (CSCI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) has a cash flow conversion efficiency ratio of -0.627x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.45 Million) by net assets ($7.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
COSCIENS Biopharma Inc. - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read COSCIENS Biopharma Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
COSCIENS Biopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSCIENS Biopharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Trinex Minerals Ltd
AU:TX3
|
-0.213x |
|
Mountain Lake Acquisition Corp. Right
NASDAQ:MLACR
|
N/A |
|
artec technologies AG
F:A6T
|
-0.014x |
|
Interbud-Lublin SA
WAR:ITB
|
-0.258x |
|
Castelbajac Co. Ltd
KQ:308100
|
-0.057x |
|
Alaunos Therapeutics Inc
NASDAQ:TCRT
|
-0.256x |
|
Polar Power Inc
NASDAQ:POLA
|
-3.278x |
|
Questor Technology Inc.
V:QST
|
-0.015x |
Annual Cash Flow Conversion Efficiency for COSCIENS Biopharma Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of COSCIENS Biopharma Inc. from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of COSCIENS Biopharma Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.16 Million | $-14.57 Million | -1.107x | -801.77% |
| 2023-12-31 | $21.04 Million | $-2.58 Million | -0.123x | -155.85% |
| 2022-12-31 | $23.79 Million | $5.23 Million | 0.220x | +73.55% |
| 2021-12-31 | $21.74 Million | $2.75 Million | 0.127x | -30.86% |
| 2020-12-31 | $19.06 Million | $3.49 Million | 0.183x | +363.33% |
| 2019-12-31 | $17.08 Million | $675.29K | 0.040x | +143.25% |
| 2018-12-31 | $17.04 Million | $-1.56 Million | -0.091x | -231.01% |
| 2017-12-31 | $17.93 Million | $1.25 Million | 0.070x | -68.00% |
| 2016-12-31 | $16.67 Million | $3.63 Million | 0.218x | -56.87% |
| 2015-12-31 | $5.68 Million | $2.87 Million | 0.506x | -50.46% |
| 2014-12-31 | $1.80 Million | $1.84 Million | 1.021x | -49.08% |
| 2013-12-31 | $229.62K | $460.21K | 2.004x | +123.19% |
| 2012-12-31 | $13.63K | $-117.82K | -8.642x | -653.59% |
| 2011-12-31 | $507.11K | $791.62K | 1.561x | +313.21% |
| 2010-12-31 | $-654.90K | $479.50K | -0.732x | -203.72% |
| 2009-12-31 | $-1.31 Million | $-925.47K | 0.706x | +23.17% |
| 2008-12-31 | $-1.59 Million | $-909.41K | 0.573x | +181.97% |
| 2007-12-31 | $1.57 Million | $-1.10 Million | -0.699x | -229.62% |
| 2006-12-31 | $260.64K | $140.59K | 0.539x | +158.09% |
| 2005-12-31 | $397.23K | $-368.84K | -0.929x | -14.94% |
| 2004-12-31 | $94.89K | $-76.65K | -0.808x | -537.56% |
| 2003-12-31 | $294.75K | $54.42K | 0.185x | +32.60% |
| 2002-12-31 | $-414.76K | $-57.75K | 0.139x | -78.26% |
| 2001-12-31 | $-714.40K | $-457.45K | 0.640x | +101.61% |
| 2000-12-31 | $-1.59 Million | $-506.44K | 0.318x | +101.16% |
| 1999-12-31 | $-1.31 Million | $-207.14K | 0.158x | -93.05% |
| 1998-12-31 | $-714.89K | $-1.62 Million | 2.273x | +574.75% |
| 1997-12-31 | $6.57 Million | $-3.14 Million | -0.479x | -101.57% |
| 1996-12-31 | $5.84 Million | $-1.39 Million | -0.237x | -- |
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more